Solo Founder Math: 82% Fail. What Survives in Life Science
On the latest Pathways in Life Science, Guillaume walked us through the 8-year arc that turned a $10,000 leap of faith into Biotech Connect, the turnkey trade show service that now anchors Canadian life science events. Worth the listen. Here’s what’s been bouncing around since: the actual data on what solo founders are up against, and why the few who survive are the ones doing things differently.
Prefer to listen? Catch the episode on Buzzsprout, Apple Podcasts, or Spotify.
The 82 percent number every solo founder should know
Industry data on bootstrapped startup survival is brutal. Roughly 82 percent of bootstrapped companies fail. The U.S. Small Business Administration’s 2024 data shows that 50.8 percent of new businesses do not survive past year five. Stack those probabilities and the math is unforgiving for anyone going alone with limited capital.
Most founders read those numbers and find a reason their venture is the exception. The honest read is that the base rate is the base rate, and beating it requires deliberate structural choices, not optimism.
Solo founders versus co-founder teams
Research on founder team composition is consistent. Solo founders are roughly three times less likely to reach a successful exit than co-founded teams. The reason is not mysterious. Two co-founders means two networks, two skill sets, two emotional support systems, and two people who can carry the load when one is depleted.
The data does not say solo founders cannot win. It says the unit economics of going alone are worse, and the founders who beat the odds tend to engineer structural workarounds early, like partner-equivalent advisors, fractional executives, or service partners who carry one full functional area.
First-time, repeat, and the experience curve
Multiple analyses show first-time founder success rates around 18 percent. Founders who failed once and tried again sit around 20 percent. Founders with one prior win climb to 30 percent. The experience curve in entrepreneurship is real, and it is steeper than most outside observers expect.
For solo founders this matters even more, because the lessons are not distributed across a team. Every mistake is yours to absorb, and the next attempt is the only place those lessons compound.
The 8-year confidence gap
Academic research on entrepreneurial impostor syndrome is now a real subfield. Reviews of founder interviews and longitudinal studies suggest that most solo founders report taking five to ten years before they feel they have legitimate command of their CEO role. The recent UCSF research published in 2025 found that 87 percent of founders report anxiety, depression, or burnout at some point in the journey, and the heaviest period is typically years two through five.
If you are 18 months in and the company still feels held together by duct tape and stress, the literature says you are exactly on schedule.
What this changes for life science founders specifically
Life science adds layers most other sectors do not. Long sales cycles. Regulatory complexity. Capital intensity. A buyer base concentrated in slow-moving institutional accounts. Solo founders in this space face the bootstrapping math plus a domain tax.
The few who succeed alone tend to do one of two things. They build service businesses with low capital intensity and recurring revenue, the path Biotech Connect took. Or they ship a product so technically narrow that one founder can credibly own the entire technical and commercial story until the first real revenue arrives.
For everyone else, the smart play is structural. A co-founder. A fractional executive partner. An outsourced commercial function that carries one big lift so the solo founder can focus on the parts only they can do. That last lever is what we spend most of our time on at North Star Scientific, and the pattern across our partner brands is consistent. Founders who stay alone on every front are the ones who burn out at year three. Founders who outsource the commercial layer get to year ten.
The takeaway
The data is not meant to scare anyone off the founder path. It is meant to inform the decision. Going solo in life science is harder than founder mythology suggests, and the operators who win do not do it by working harder. They do it by building structures that make the base rate matter less.
Want the full conversation with Guillaume? Hit play above or grab the episode on your platform of choice. And if you are a life science founder thinking about how to outsource the commercial lift while you focus on the science, come talk to us.
